Market research
OCS Oculis Holding AG Ordinary shares
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 732M
- P/E ratio
- Not available
- Analyst target
- 36.342
- Dividend yield
- Not available
- Beta
- 0.23
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CH1242303498
- Market cap
- 732M
- P/E ratio
- Not available
- Analyst target
- 36.342
- Dividend yield
- Not available
- Beta
- 0.23
About
About Oculis Holding AG Ordinary shares
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the OCS discussion.
No comments yet
Start a focused discussion about OCS.